EA036704B1 - Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита - Google Patents
Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита Download PDFInfo
- Publication number
- EA036704B1 EA036704B1 EA201692050A EA201692050A EA036704B1 EA 036704 B1 EA036704 B1 EA 036704B1 EA 201692050 A EA201692050 A EA 201692050A EA 201692050 A EA201692050 A EA 201692050A EA 036704 B1 EA036704 B1 EA 036704B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nash
- nafld
- mbx
- treatment
- alcoholic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978335P | 2014-04-11 | 2014-04-11 | |
| PCT/US2015/025416 WO2015157697A1 (en) | 2014-04-11 | 2015-04-10 | Treatment of nafld and nash |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201692050A1 EA201692050A1 (ru) | 2017-01-30 |
| EA036704B1 true EA036704B1 (ru) | 2020-12-10 |
Family
ID=53373532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201692050A EA036704B1 (ru) | 2014-04-11 | 2015-04-10 | Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US9381181B2 (OSRAM) |
| EP (1) | EP3129018B1 (OSRAM) |
| JP (1) | JP6865038B2 (OSRAM) |
| KR (1) | KR102374499B1 (OSRAM) |
| CN (1) | CN106163508A (OSRAM) |
| AU (1) | AU2015243239B2 (OSRAM) |
| BR (1) | BR112016023269A8 (OSRAM) |
| CA (1) | CA2944139C (OSRAM) |
| CL (1) | CL2016002517A1 (OSRAM) |
| CY (1) | CY1122602T1 (OSRAM) |
| DK (1) | DK3129018T3 (OSRAM) |
| EA (1) | EA036704B1 (OSRAM) |
| ES (1) | ES2764467T3 (OSRAM) |
| HR (1) | HRP20192299T1 (OSRAM) |
| IL (1) | IL248193B (OSRAM) |
| LT (1) | LT3129018T (OSRAM) |
| MX (1) | MX369921B (OSRAM) |
| NZ (1) | NZ724740A (OSRAM) |
| PH (1) | PH12016501978B1 (OSRAM) |
| PL (1) | PL3129018T3 (OSRAM) |
| PT (1) | PT3129018T (OSRAM) |
| RS (1) | RS59637B1 (OSRAM) |
| SG (1) | SG11201608077PA (OSRAM) |
| SI (1) | SI3129018T1 (OSRAM) |
| SM (1) | SMT202000019T1 (OSRAM) |
| UA (1) | UA121208C2 (OSRAM) |
| WO (1) | WO2015157697A1 (OSRAM) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| JP5694941B2 (ja) * | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| MX2011011517A (es) | 2009-04-29 | 2012-06-19 | Amarin Corp Plc | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. |
| CN102458109B (zh) | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | 稳定的药物组合物和使用其的方法 |
| LT2443246T (lt) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| WO2013103958A1 (en) | 2012-01-06 | 2013-07-11 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| BR112014032905B1 (pt) | 2012-06-29 | 2022-02-22 | Amarin Pharmaceuticals Ireland Limited | Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US9814733B2 (en) * | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| SI3119384T1 (sl) | 2014-03-20 | 2018-12-31 | Cymabay Therapeutics, Inc. | Zdravljenje intrahepatičnih holestatičnih bolezni |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| HRP20192299T1 (hr) | 2014-04-11 | 2020-03-06 | Cymabay Therapeutics, Inc. | Liječenje nafld i nash |
| EP3149156B1 (en) | 2014-05-28 | 2021-02-17 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| JP6804438B2 (ja) | 2014-10-17 | 2020-12-23 | チルドレンズ ホスピタル メディカル センター | 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法 |
| WO2016154258A1 (en) * | 2015-03-26 | 2016-09-29 | T3D Therapeutics, Inc. | Methods of treating liver disease using indane acetic acid derivatives |
| BR112017023164A2 (en) | 2015-04-28 | 2018-07-24 | Pronova Biopharma Norge As | and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof |
| WO2017049157A1 (en) * | 2015-09-18 | 2017-03-23 | Duke University | Methods and compositions for the treatment of steatosis-associated disorders |
| WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| GB201614455D0 (en) | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| EP3534976A4 (en) | 2016-11-04 | 2020-09-16 | Children's Hospital Medical Center | PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE |
| US10493363B2 (en) * | 2016-11-09 | 2019-12-03 | Activision Publishing, Inc. | Reality-based video game elements |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| EP3619193B1 (en) | 2017-05-05 | 2023-03-22 | Hepanova, Inc. | Amino-aryl-benzamide compounds and methods of use thereof |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| US20200276178A1 (en) | 2017-09-13 | 2020-09-03 | Novartis Ag | Combinations comprising fxr agonists |
| EP3694603A4 (en) | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| JP6976030B2 (ja) * | 2017-10-27 | 2021-12-01 | サムヤン コーポレイション | 非アルコール性脂肪肝疾患の予防または改善用組成物 |
| BR112020011431A2 (pt) | 2017-12-06 | 2020-11-24 | Basf As | derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| CA3118965A1 (en) | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Treatment of obesity and its complications |
| KR20210092754A (ko) * | 2018-11-16 | 2021-07-26 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash의 병용 치료 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN114375193B (zh) | 2019-09-12 | 2024-05-14 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
| CN114980973A (zh) | 2019-11-12 | 2022-08-30 | 阿马里纳药物爱尔兰有限公司 | 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法 |
| US20210145775A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
| WO2021097027A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of alcoholic liver disease |
| IL298144A (en) * | 2020-05-13 | 2023-01-01 | Terns Pharmaceuticals Inc | Combination treatment of liver disorders |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| AU2022274304A1 (en) * | 2021-05-11 | 2023-10-26 | Genfit | Ppar-agonists for use in the treatment of liver failure |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033231A2 (en) * | 2005-09-14 | 2007-03-22 | Janssen Pharmaceutica N.V. | Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| EP0813539B1 (en) | 1995-03-06 | 2006-05-24 | Isis Pharmaceuticals, Inc. | Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| ES2221039T3 (es) | 1996-02-14 | 2004-12-16 | Isis Pharmaceuticals, Inc. | Oligonucleotidos abiertos modificados con azucar. |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| ATE542793T1 (de) | 2003-09-19 | 2012-02-15 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga |
| JP5697296B2 (ja) | 2004-03-05 | 2015-04-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法 |
| US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| JP5694941B2 (ja) | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| CN105764498A (zh) | 2013-11-20 | 2016-07-13 | 西玛贝医药公司 | 纯合家族型高胆固醇血症的治疗 |
| SI3119384T1 (sl) | 2014-03-20 | 2018-12-31 | Cymabay Therapeutics, Inc. | Zdravljenje intrahepatičnih holestatičnih bolezni |
| HRP20192299T1 (hr) | 2014-04-11 | 2020-03-06 | Cymabay Therapeutics, Inc. | Liječenje nafld i nash |
| BR112016028918A2 (pt) | 2014-06-26 | 2017-08-22 | Cymabay Therapeutics Inc | tratamento de hipertrigliceridemia grave |
-
2015
- 2015-04-10 HR HRP20192299TT patent/HRP20192299T1/hr unknown
- 2015-04-10 US US14/684,100 patent/US9381181B2/en active Active
- 2015-04-10 LT LTEP15728222.9T patent/LT3129018T/lt unknown
- 2015-04-10 RS RS20191583A patent/RS59637B1/sr unknown
- 2015-04-10 UA UAA201609927A patent/UA121208C2/uk unknown
- 2015-04-10 CN CN201580018550.9A patent/CN106163508A/zh active Pending
- 2015-04-10 EA EA201692050A patent/EA036704B1/ru unknown
- 2015-04-10 KR KR1020167031356A patent/KR102374499B1/ko active Active
- 2015-04-10 ES ES15728222T patent/ES2764467T3/es active Active
- 2015-04-10 MX MX2016013375A patent/MX369921B/es active IP Right Grant
- 2015-04-10 PH PH1/2016/501978A patent/PH12016501978B1/en unknown
- 2015-04-10 NZ NZ72474015A patent/NZ724740A/en unknown
- 2015-04-10 BR BR112016023269A patent/BR112016023269A8/pt not_active Application Discontinuation
- 2015-04-10 DK DK15728222.9T patent/DK3129018T3/da active
- 2015-04-10 AU AU2015243239A patent/AU2015243239B2/en active Active
- 2015-04-10 SG SG11201608077PA patent/SG11201608077PA/en unknown
- 2015-04-10 SM SM20200019T patent/SMT202000019T1/it unknown
- 2015-04-10 PL PL15728222T patent/PL3129018T3/pl unknown
- 2015-04-10 SI SI201531047T patent/SI3129018T1/sl unknown
- 2015-04-10 WO PCT/US2015/025416 patent/WO2015157697A1/en not_active Ceased
- 2015-04-10 PT PT157282229T patent/PT3129018T/pt unknown
- 2015-04-10 CA CA2944139A patent/CA2944139C/en active Active
- 2015-04-10 JP JP2016561799A patent/JP6865038B2/ja active Active
- 2015-04-10 EP EP15728222.9A patent/EP3129018B1/en active Active
-
2016
- 2016-06-02 US US15/171,910 patent/US9616039B2/en active Active
- 2016-10-04 CL CL2016002517A patent/CL2016002517A1/es unknown
- 2016-10-05 IL IL248193A patent/IL248193B/en active IP Right Grant
-
2017
- 2017-03-02 US US15/447,895 patent/US9962346B2/en active Active
-
2018
- 2018-04-03 US US15/943,936 patent/US10188620B2/en active Active
- 2018-12-17 US US16/222,379 patent/US10342770B2/en active Active
-
2019
- 2019-05-23 US US16/420,465 patent/US10722483B2/en active Active
- 2019-12-20 CY CY20191101347T patent/CY1122602T1/el unknown
-
2020
- 2020-06-19 US US16/906,296 patent/US11179359B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033231A2 (en) * | 2005-09-14 | 2007-03-22 | Janssen Pharmaceutica N.V. | Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives |
Non-Patent Citations (2)
| Title |
|---|
| BAYS HAROLD E ET AL: "MBX-8025, A Novel Peroxisome Proliferator Receptor-delta Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 96, no. 9, 13 June 2012 (2012-06-13), US, pages 2889 - 2897, XP002677652, ISSN: 0021-972X * |
| SAHEBKAR, AMIRHOSSEIN; CHEW, GERARD T.; WATTS, GERALD F.: "New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease", EXPERT OPIN PHARMACOTHER, ASHLEY PUBLICATIONS LTD, LONDON, UK, vol. 15, no. 4, 1 March 2014 (2014-03-01), London, UK, pages 493 - 503, XP009182172, ISSN: 1465-6566, DOI: 10.1517/14656566.2014.876992 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11179359B2 (en) | Treatment of NAFLD and NASH | |
| JP6568577B2 (ja) | 肝内胆汁うっ滞症の治療 | |
| WO2020102351A1 (en) | Treatment of obesity and its complications | |
| KR20210092754A (ko) | Nafld 및 nash의 병용 치료 | |
| KR102408288B1 (ko) | 간내 담즙 정체성 질환의 치료 | |
| HK1228275A1 (en) | Treatment of nafld and nash | |
| HK1228275B (en) | Treatment of nafld and nash |